Diligence memo · auto-generated · as of July 3, 2026
Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Protagenic Therapeutics Inc. operates in Biotechnology, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Protagenic Therapeutics Inc. has raised $1.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $643K on 2013-02-15.
Most recent recorded round closed around 2013-02-15.
Valuation (modeled)modeled
Provath models Protagenic Therapeutics Inc. at approximately $35M (range $343K–$402M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.24× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 29 months.
Last raise 13.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 19% of Biotechnology peers (4293 compared).
Modeled value ranks above 38% of those peers.
Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.